Based on the data in the noted references, ponatinib was added as a treatment option in the following circumstances:

- **Chronic phase CML**
  - For patients with inadequate initial response to prior TKI therapy
    - BCR-ABL/ABL transcript levels > 10% (IS) or < partial cytogenetic response (PCyR) on bone marrow cytogenetics at 3 months
    - Less than complete cytogenetic response (CCyR) at 12 and 18 months
  - Continuation of therapy for patients (who have been switched to ponatinib as early as 3 months for inadequate initial response to prior TKI therapy) in CCyR 12 months and 18 months or PCyR at 12 months
  - Loss of response (increase in BCR-ABL transcript levels or cytogenetic relapse) at 6, 12 and 18 months
- Disease progression to accelerated or blast phase CML on prior TKI therapy.
- Follow-up therapy for relapse following allogeneic HSCT
- Preferred treatment option for patients with T315I mutation